Gary Yeung

David is Chief Financial Officer of Erasca, providing deep experience in strategy, finance, business development and operations. He joined the company in 2019 as Chief Business Officer with oversight of its corporate and business development efforts. Prior to Erasca, he was a Principal at Versant Ventures, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. David joined Versant from Alcon, where, as Chief of Staff to the CEO, he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, David was an Engagement Manager at McKinsey, leading multiple teams serving pharmaceutical and medical device clients, across sales and marketing, R&D, finance and other functions. Previously, David worked at SR One, the venture capital arm of GSK. He also worked at Amgen in commercial operations and at Morgan Stanley in investment banking.

David holds an M.D. from the University of Pennsylvania, where he was President of the medical student body, and an MBA from the Wharton School. He earned an MPhil from Oxford University as a Marshall Scholar, as well as undergraduate degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian.